摘要目的:探讨阿托伐他汀和普伐他汀治疗高龄冠状动脉粥样硬化性心脏病(CHD)的效果。方法:选取2018年9月至2019年2月厦门弘爱医院老年科收治的100例年龄≥80岁的CHD患者，对其临床资料进行回顾性分析，男61例，女39例，年龄(87.50±2.34)岁，年龄范围为80~92岁。根据治疗方法不同将患者分为阿托伐他汀组及普伐他汀组，每组50例。阿托伐他汀组采用阿托伐他汀20 mg/d，普伐他汀组采用普伐他汀40 mg/d，连续服药12周，比较治疗后两组患者血脂水平[总胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白]、治疗效果、谷丙转氨酶、谷草转氨酶、肌酸激酶、血肌酐水平变化情况及不良反应发生情况。结果:阿托伐他汀组患者降脂效果[92.0%(46/50)]优于普伐他汀组[80.0%(40/50)]，差异有统计学意义( P<0.05)。治疗后，阿托伐他汀组与普伐他汀组患者血脂水平比较，差异无统计学意义( P>0.05)；阿托伐他汀组与普伐他汀组患者谷丙转氨酶、谷草转氨酶、肌酸激酶及血肌酐比较，差异无统计学意义( P>0.05)；两组患者不良反应发生情况比较，差异无统计学意义( P>0.05)。 结论:阿托伐他汀与普伐他汀均可有效治疗高龄CHD，在患者不良反应发生情况、血脂水平、谷丙转氨酶、谷草转氨酶、肌酸激酶及血肌酐水平等方面均无显著差异。

abstractsObjective:To investigate the effect of atorvastatin and pravastatin on elderly patients with coronary atherosclerotic heart disease(CHD).Methods:A total of 100 patients with CHD aged ≥80 years who were admitted to Geriatrics department of Xiamen Hongai Hospital from September 2018 to February 2019 were selected for retrospective analysis of their clinical data, including 61 males and 39 females, aged(87.50±2.34)years, ranging from 80 to 92 years.Patients were divided into atorvastatin group and pravastatin group according to different treatment methods, with 50 patients in each group.Atorvastatin group received atorvastatin 20 mg/d, pravastatin group received pravastatin 40 mg/d for 12 weeks.After treatment, blood lipid levels[total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein], treatment effects, changes in glutamic-pyruvic transaminase, glutamic-oxalacetic transaminase, creatine kinase, serum creatinine levels and the occurrence of adverse reactions were compared between the two groups.Results:The lipid-lowering effect of atorvastatin group[92.0%(46/50)]was better than pravastatin group[80.0%(40/50)], and the difference was statistically significant( P<0.05). After treatment, there was no significant difference in blood lipid levels between atorvastatin group and pravastatin group( P>0.05). There were no significant differences in alanine aminotransferase, aspartate aminotransferase, creatine kinase and serum creatinine between atorvastatin group and pravastatin group( P>0.05). There was no statistical significance in the occurrence of adverse reactions between 2 groups( P>0.05). Conclusion:Both atorvastatin and pravastatin can effectively treat elderly CHD, and there were no significant differences in the incidence of adverse reactions, blood lipid levels, alanine aminotransferase, aspartate aminotransferase, creatine kinase and serum creatinine levels in patients.